An adaptive servo-ventilation (ASV) machine is a type of positive airway pressure device engineered specifically to treat central sleep apnea and unstable breathing patterns that simpler machines like CPAP struggle to control. Unlike standard CPAP, which delivers a single fixed pressure, ASV continuously monitors your breathing and adjusts its support breath by breath, working against the irregular cycling that defines central apnea. The technology occupies a particular niche in sleep medicine, one shaped by strong evidence of benefit in some patients and a landmark safety warning that changed how clinicians prescribe it.
How ASV Differs From CPAP and BiPAP
Standard CPAP pushes a constant stream of air at one set pressure to keep your upper airway open. That works well for obstructive sleep apnea, where the problem is a physical collapse of throat tissue. BiPAP goes a step further by offering two pressures: a higher one when you breathe in and a lower one when you breathe out, which helps people who need more support or have trouble exhaling against pressure. Both devices, however, are essentially passive. They deliver pressure and wait for you to breathe.
ASV does something fundamentally different. It monitors your airflow or minute ventilation on an ongoing basis, calculates a target ventilation, and then adjusts the inspiratory pressure continuously to keep you close to that target. When your breathing starts to wane, the machine ramps up support. When your breathing strengthens, it backs off. It also applies pressure support that runs counter to your respiratory cycle, dampening the crescendo-decrescendo pattern characteristic of periodic breathing. A backup breathing rate kicks in if you stop breathing altogether. The net effect is a device that actively stabilizes ventilation rather than simply holding an airway open.1PubMed. Positive airway pressure therapy with adaptive servoventilation: part 1: operational algorithms
This responsive behavior is what makes ASV suited for central sleep apnea, where the brain intermittently fails to signal the muscles to breathe. CPAP cannot fix a problem that has nothing to do with airway collapse, and in some cases it makes things worse.
The Breathing Problem ASV Is Built to Solve
Central sleep apnea (CSA) stems from instability in the brain’s respiratory control system. During sleep, your breathing is driven largely by carbon dioxide levels in the blood. If you hyperventilate slightly, COâ‚‚ drops below a threshold and the brain simply stops sending the “breathe” signal until COâ‚‚ builds back up. This produces a rhythmic waxing and waning of breathing effort that clinicians call Cheyne-Stokes respiration when it follows a particular crescendo-decrescendo pattern. Several factors can push someone toward this instability: pulmonary congestion stimulating lung receptors, heightened sensitivity of chemoreceptors, reduced blood flow to the brain, and repeated arousals from sleep that trigger brief hyperventilation.2PubMed. Central sleep apnea and Cheyne-Stokes respiration
This is common in people with heart failure, but it also occurs after stroke, during opioid use, and sometimes seemingly out of nowhere. The key distinction is that the airway itself is not blocked. The muscles and tissues are fine. The respiratory drive is what falters. That is why a device that actively modulates ventilation, rather than one that simply splints open the throat, is the logical tool.
Treatment-Emergent Central Sleep Apnea
One of the more frustrating scenarios in sleep medicine is when a patient starts CPAP for obstructive sleep apnea and develops central apneas they did not have before. This is called treatment-emergent central sleep apnea (TE-CSA), sometimes referred to as complex sleep apnea. The obstructive events clear up, but new central events appear, leaving the patient with a residual breathing disturbance that CPAP cannot resolve and that often makes the patient feel no better.
ASV has become the primary tool for managing TE-CSA when continued CPAP or BiPAP does not help. In a prospective randomized trial comparing ASV to CPAP in patients who developed central apneas on CPAP, roughly 90% of ASV-treated patients achieved a breathing disturbance index below the clinical threshold of ten events per hour at 90 days, compared with about 65% on CPAP.3PubMed Central. The Complex Sleep Apnea Resolution Study: A Prospective Randomized Controlled Trial of Continuous Positive Airway Pressure Versus Adaptive Servoventilation Therapy Central apnea events specifically were driven much lower on ASV, confirming that the device’s breath-by-breath adjustment addresses the mechanism that CPAP does not.4PubMed Central. Treatment-emergent central sleep apnea: a unique sleep-disordered breathing
Registry data also show that quality-of-life scores and daytime sleepiness improve on ASV in TE-CSA patients regardless of whether they have underlying cardiovascular disease.5Annals of the American Thoracic Society. Adaptive Servo-Ventilation for Treatment-Emergent Central Sleep Apnea: The READ-ASV Registry
ASV Versus Other Devices in Head-to-Head Comparisons
For central, mixed, and complex apnea syndromes, ASV consistently outperforms both CPAP and bilevel devices with backup rates in controlled studies. One trial titrating patients with CSA, Cheyne-Stokes respiration, and complex sleep apnea found that CPAP left a mean breathing disturbance index above 34 events per hour. Both bilevel ventilation and ASV brought that number into the normal range, but ASV did so more completely, averaging less than one event per hour compared with about six on bilevel therapy.6SLEEP. Adaptive Servoventilation Versus Noninvasive Positive Pressure Ventilation For Central, Mixed, And Complex Sleep Apnea Syndromes
In opioid-associated central sleep apnea, a separate trial found ASV normalized breathing in over 80% of patients during titration, compared with a third on bilevel ventilation with a backup rate. Patients also reported feeling more alert the next morning on ASV.7PubMed Central. A Novel Adaptive Servoventilation (ASVAuto) for the Treatment of Central Sleep Apnea Associated with Chronic Use of Opioids Long-term follow-up of opioid patients on ASV, some tracked for up to six years, showed that the central apnea index dropped to zero on treatment and that average nightly use hovered around five hours, which is solid adherence for any positive airway pressure device.8PubMed Central. Adaptive servoventilation for treatment of opioid-associated central sleep apnea
The SERVE-HF Warning and Heart Failure With Reduced Ejection Fraction
No discussion of ASV is complete without addressing the trial that reshaped how the device is prescribed. In 2015, the SERVE-HF trial enrolled over 1,300 patients with heart failure and reduced ejection fraction (HFrEF) who also had central sleep apnea. The expectation was that treating the sleep apnea would improve cardiovascular outcomes. Instead, the trial found the opposite: patients randomized to ASV had a roughly 28% higher risk of death from any cause and a 34% higher risk of cardiovascular death compared to the control group.9PubMed Central. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure
The results prompted device manufacturers to add contraindication warnings and led medical societies to recommend against using ASV in patients with symptomatic heart failure and a left ventricular ejection fraction at or below 45%. A subsequent analysis of the same trial confirmed that while the composite primary endpoint of death, life-saving intervention, or hospital admission was statistically neutral, the mortality signal was real and troubling.10The Lancet Respiratory Medicine. Multistate analysis of the SERVE-HF trial investigating effects of adaptive servoventilation on central sleep apnoea in heart failure
Why ASV might harm these patients is still debated. One theory focuses on how the device alters cardiac pressures. In heart failure patients with elevated right ventricular pressures, ASV can increase cardiac output through favorable changes in filling pressure. But in patients whose hearts are failing in a different hemodynamic pattern, that same pressure support may not help and could impose additional cardiopulmonary stress.11J-STAGE / International Heart Journal. Right Ventricular End-Diastolic Pressure Is a Key to the Changes in Cardiac Output During Adaptive Servo-Ventilation Support in Patients With Heart Failure Another line of thinking holds that central sleep apnea in severe heart failure may be a compensatory mechanism rather than a disease state, and suppressing it with ASV removes a protective reflex. The honest answer is that the mechanism of harm is not settled.
Heart Failure With Preserved Ejection Fraction Is a Different Story
The SERVE-HF findings apply specifically to heart failure with reduced ejection fraction. In patients whose hearts pump normally but fill poorly, a condition known as heart failure with preserved ejection fraction (HFpEF), the limited evidence available paints a more encouraging picture. One study found that ASV improved diastolic heart function, reduced a marker of cardiac stress, and was associated with significantly fewer adverse cardiac events over follow-up compared to a non-ASV control group.12PubMed. Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing
A more recent study of HFpEF patients found that heart failure hospitalizations dropped substantially after patients started ASV, with the median number of hospitalizations per patient falling from one in the year before treatment to zero in the year after. The study also suggested that women, patients with lower body mass index, and those with significant tricuspid valve regurgitation may benefit most.13PubMed. The efficacy and safety of adaptive servo-ventilation therapy for heart failure with preserved ejection fraction These are smaller studies than SERVE-HF, and no large randomized trial has definitively established safety and benefit in HFpEF. But the data are promising enough that clinicians continue to use ASV in this population, with careful monitoring.
Adherence and Patient Experience
One of the persistent challenges with any positive airway pressure device is getting people to actually use it every night. ASV fares well on this front. A large analysis of device usage data found that patients who switched from CPAP to ASV went from an adherence rate of about 63% on CPAP to roughly 77% on ASV, with average nightly use climbing to nearly six hours. Patients who started directly on ASV had comparable adherence to those on CPAP alone, around 73%.14PubMed Central. Adherence to Positive Airway Therapy After Switching From CPAP to ASV: A Big Data Analysis
The improvement in adherence among switchers is telling. Many of these patients had been struggling with CPAP, presumably because CPAP was not resolving their central events and the experience of wearing the device without feeling better eroded motivation. When the treatment actually works, people are more willing to tolerate it. A six-month study comparing ASV and CPAP in Cheyne-Stokes respiration found that while adherence was similar at three months, CPAP adherence dropped off significantly by six months, whereas ASV adherence held steady.15Heart. Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period
ASV After Stroke
Central sleep apnea is common after ischemic stroke, affecting a sizable minority of patients and often persisting for months. Standard CPAP does little for these central events, and untreated sleep-disordered breathing after stroke is associated with worse neurological recovery. A study of post-stroke patients with persistent CSA found that ASV brought the average breathing disturbance index down from about 47 events per hour to under nine, with the effect maintained at six months. Daytime sleepiness also improved, and average nightly use of roughly five and a half hours suggested good tolerance.16PubMed. Adaptive servo-ventilation as treatment of persistent central sleep apnea in post-acute ischemic stroke patients This is still a small evidence base, and most stroke patients will not need ASV. But for those with stubborn central apneas that do not resolve on their own or with CPAP, it fills a gap that other devices cannot.
Acute Pulmonary Edema and Sympathetic Effects
There is emerging interest in using ASV in acute settings, not just as a long-term home therapy. In acute cardiogenic pulmonary edema, patients struggle with severe shortness of breath partly driven by fluid in the lungs and partly by a surge of stress hormones. A study comparing ASV to standard oxygen therapy in this setting found that within the first hour, ASV produced significant drops in blood pressure, heart rate, respiratory rate, and circulating catecholamine levels, the hormones that drive the “fight or flight” stress response. Patients on ASV also reported more relief from breathlessness than those on oxygen alone.17European Heart Journal. Acute Cardiovascular Care. The effect of adaptive servo-ventilation on dyspnoea, haemodynamic parameters and plasma catecholamine concentrations in acute cardiogenic pulmonary oedema
The sympathetic calming effect is worth noting. Heart failure and central sleep apnea create a vicious cycle where apneas trigger arousals, arousals spike adrenaline, and elevated adrenaline worsens the heart’s workload. If ASV can break that cycle, the benefits extend beyond the sleep lab. Of course, applying ASV in acute care requires different clinical judgment than prescribing it for long-term home use, and the SERVE-HF contraindication in HFrEF still applies.
Healthcare Costs and Hospitalization
ASV devices are substantially more expensive than CPAP machines, often costing two to three times as much. Insurance coverage varies and frequently requires documentation of failed CPAP therapy before an ASV prescription will be approved. But the cost calculation looks different when hospitalizations enter the picture. A study of chronic heart failure patients found that total medical costs dropped by about 37% after starting ASV, driven primarily by fewer hospital readmissions.18PubMed. Beneficial effects of adaptive servo-ventilation therapy on readmission and medical costs in patients with chronic heart failure For patients whose sleep-disordered breathing contributes to repeated emergency department visits and hospitalizations, the upfront device cost can be a relatively small part of the overall financial picture.
Where ASV Falls Short
ASV is not a universal solution even within the world of central sleep apnea. At high altitude, where healthy individuals develop periodic breathing because of the low oxygen environment, a small trial found that ASV did not significantly reduce oxygen desaturation events compared to no treatment. Supplemental oxygen, by contrast, resolved the central apneas effectively.19PubMed Central. Adaptive Servoventilation as Treatment for Central Sleep Apnea Due to High-Altitude Periodic Breathing in Nonacclimatized Healthy Individuals The likely explanation is that altitude-induced periodic breathing has a different physiological driver, low ambient oxygen rather than the COâ‚‚-driven instability ASV is designed to counteract, and what the body needs is simply more oxygen, not pressure support that modulates ventilation.
In pediatric patients, the evidence is confined almost entirely to case reports. Individual cases describe infants and children with combined central and obstructive apnea who did not respond to CPAP or BiPAP but improved on ASV.20Journal of Sleep Disorders: Treatment and Care. Adaptive Servo Ventilation to Treat an Infant with both Central and Obstructive Sleep Apnea One case documented growth improvement in a child after ten months on ASV following persistent high residual breathing disturbances on CPAP.21PubMed Central. Persistent High Residual AHI After CPAP Use But there are no pediatric trials, and the devices are designed and pressure-calibrated for adult physiology. Using ASV in children remains an off-label, last-resort decision made case by case.
How ASV Settings Are Tailored in Practice
ASV devices have several adjustable parameters, and getting them right matters. The machines control an expiratory pressure that keeps the upper airway open, similar to CPAP, along with a variable inspiratory pressure support range that the device adjusts automatically. Some models also allow clinicians to set targets based on minute ventilation rather than simple airflow, which may be more physiologically appropriate for certain patients.
A real-world multicenter study examining ASV settings across nearly 180 patients found that settings did not differ much based on the type of sleep-disordered breathing. What did matter was the patient’s broader clinical profile. Patients with obesity and heart disease, for instance, tended to need different expiratory pressure settings than lean patients without cardiac problems. Patients with predominant obstructive events and low ejection fraction received lower fixed expiratory pressures, while those with treatment-emergent central apnea and no heart disease more often used the auto-adjusting expiratory pressure feature.22PubMed Central. Patterns of adaptive servo-ventilation settings in a real-life multicenter study: pay attention to volume! The takeaway for patients is that ASV is not a plug-and-play device. Getting it dialed in usually requires at least one in-lab titration study and follow-up adjustments based on download data from the machine.
Remote monitoring has made those follow-up adjustments more practical. Most current ASV models transmit usage data and breathing event indices wirelessly to cloud platforms that the prescribing clinician can review, allowing pressure changes without requiring the patient to come back to the sleep lab every time. For patients in rural areas or those with mobility limitations, this connectivity can make the difference between a well-tuned therapy and one that quietly underperforms for months.